General
Preferred name
LINEZOLID
Synonyms
PNU-100766 ()
Linezolid (PNU-100766) ()
Zyvoxid, Zyvoxam,PNU-100766 ()
Linezolid-d3 ()
Zyvox ()
U-100,766 ()
Linezolide ()
U-100766 ()
P&D ID
PD001291
CAS
165800-03-3
1127120-38-0
Tags
available
drug
Approved by
FDA
First approval
2000
Drug indication
infection
Bacterial infection
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Linezolid is a synthetic oxazolidinone class antibacterial with activity against Gram-positive pathogens . It also has activity as a MAO (monoamine oxidase) inhibitor. (GtoPdb)
DESCRIPTION Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics[1][2][3].
PRICE 35
DESCRIPTION Antibiotic; inhibits 50S ribosomal subunit formation and elongation at transpeptidation (Tocris Bioactive Compound Library)
DESCRIPTION Antibiotic; inhibits protein synthesis in gram-positive bacteria (Tocriscreen Plus)
DESCRIPTION Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). Linezolid works by inhibiting the initiation of bacterial protein synthesis. (Enamine Bioactive Compounds)
DESCRIPTION Linezolid (PNU-100766), the first of the oxazolidinone class, is a synthetic antibiotic used for the therapy of infections resulted from multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and streptococcus. The drug takes effect as the inhibitor of the initiation of bacterial protein synthesis. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
7
Compound Sets
26
AdooQ Bioactive Compound Library
A10533
Axon Medchem Screening Library
2048
Cayman Chemical Bioactives
15012
25038
ChEMBL Approved Drugs
CHEMBL126
ChEMBL Drugs
CHEMBL126
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00601
DrugBank Approved Drugs
DB00601
DrugCentral
1584
DrugCentral Approved Drugs
1584
DrugMAP
DMGFPU2
DrugMAP Approved Drugs
DMGFPU2
Enamine Bioactive Compounds
EBC-08517
Enamine BioReference Compounds
Guide to Pharmacology
10827
MedChem Express Bioactive Compound Library
HY-10394
NCATS Inxight Approved Drugs
ISQ9I6J12J
NIH Clinical Collections (NCC)
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Linezolid(Zyvox)
TargetMol Bioactive Compound Library
T0391
The Spectrum Collection
Tocris Bioactive Compound Library
3765
Tocriscreen Plus
3765
External IDs
52
Properties
(calculated by RDKit )
Molecular Weight
337.14
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
1
cLogP
1.12
TPSA
71.11
Fraction CSP3
0.5
Chiral centers
1.0
Largest ring
6.0
QED
0.89
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Cell Biology
Target
antibiotic
AOA
AOB
Bacterial
MAOA, MAOB
Primary Target
DNA, RNA and Protein Synthesis
MOA
Inhibitor
bacterial 50S ribosomal subunit inhibitor
Indication
pneumonia, skin infections
Pathway
Metabolism
Microbiology/virology
Neuroscience
Anti-infection
Therapeutic Class
Antibiotics
Source data